Market Place
Sourcing Support
Allogene Announces December Investor Conference Participation
19 Nov 2024 //
GLOBENEWSWIRE
Allogene Presents ALLO-329 Data for Autoimmune Disease at ACR
18 Nov 2024 //
GLOBENEWSWIRE
Allogene abandons leukemia CAR-T plans after Breyanzi approval
14 Nov 2024 //
FIERCE BIOTECH
Allogene links solid tumor CAR-T to responses, deaths in phase 1
08 Nov 2024 //
FIERCE BIOTECH
Allogene Reports Phase 1 Data on ALLO-316 in Renal Cancer at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Allogene Presents ALLO-316 Data in Renal Cell Carcinoma at IKCS
05 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Participate in Nov Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Report Q3 2024 Results & Update
30 Oct 2024 //
GLOBENEWSWIRE
Allogene Receives FDA RMAT Designation for ALLO-316 in RCC
29 Oct 2024 //
GLOBENEWSWIRE
Allogene participate Goldman Sachs Cell Therapy Day Conference
30 Sep 2024 //
GLOBENEWSWIRE
Allogene To Present Data On ALLO-329 At ACR Convergence
26 Sep 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08 Aug 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Q2 2024 Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Allogene Therapeutics To Report Q2 2024 Results
31 Jul 2024 //
GLOBENEWSWIRE
Allogene Activates Sites For ALPHA3 Trial Of Cema-cel In LBCL
01 Jul 2024 //
GLOBENEWSWIRE
Allogene Starts Phase 2 Trial For CAR T Product In Large B-Cell Lymphoma
20 Jun 2024 //
GLOBENEWSWIRE
Allogene Oncology Summit Featured: Cowen Participation Scheduled 2024
23 May 2024 //
GLOBENEWSWIRE
Allogene`s $110M offering
13 May 2024 //
PRESS RELEASE
Allogene Therapeutics Q1 2024 Financials, Business Update
13 May 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
13 May 2024 //
GLOBENEWSWIRE
Allogene To Report Q1 Results, Provide Business Update
06 May 2024 //
GLOBENEWSWIRE
Allogene Awarded CIRM Grant for Allogeneic CAR-T in Renal Cell Cancer
26 Apr 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Q2 Investor Conference Participation
09 Apr 2024 //
GLOBENEWSWIRE
Allogene Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
Allogene Therapeutics and Arbor Biotechnologies Announce Agreement
12 Mar 2024 //
GLOBENEWSWIRE
Allogene to Report Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Allogene Announces Participation in 44th Annual TD Cowen Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Allogene Therapeutics to Restate Previously Filed Financial Statements
16 Feb 2024 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
16 Jan 2024 //
GLOBENEWSWIRE
Allogene makes `bold` pivot, stopping pivotal trials in pursuit of first-line CAR-T cures
06 Jan 2024 //
FIERCE BIOTECH
Allogene Announces Vision to Redefine Future of CAR T Led by ALPHA3
04 Jan 2024 //
GLOBENEWSWIRE
Allogene Therapeutics and Foresight Diagnostics Announce Partnership
04 Jan 2024 //
GLOBENEWSWIRE
Allogene to Host Conference Call Previewing its 2024 Platform Vision
03 Jan 2024 //
GLOBENEWSWIRE
Allogene Presents Safety Data of Proprietary Lymphodepletion Agent ALLO-647
09 Dec 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in December Investor Conference
01 Dec 2023 //
GLOBENEWSWIRE
Allogene Presents Data on Allogeneic CAR T Product Targeting Claudin18.2
03 Nov 2023 //
GLOBENEWSWIRE
Allogene Presents Preclinical Data on Next Generation Cloak and Dagger
03 Nov 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting
02 Nov 2023 //
GLOBENEWSWIRE
Allogene Reports Third Quarter 2023 Financial Results and Business Update
02 Nov 2023 //
GLOBENEWSWIRE
Allogene to Report Third Quarter 2023 Financial Results on November 2, 2023
26 Oct 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
16 Oct 2023 //
GLOBENEWSWIRE
Allogene Announces Three Poster Presentations from its Next Generation AlloCAR T
27 Sep 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Participation in September Investor Conference
05 Sep 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Allogene to Report Second Quarter 2023 Financial Results on August 2, 2023
26 Jul 2023 //
GLOBENEWSWIRE
Allogene to ramp up enrolment in Phase II CAR-T trials
16 Jun 2023 //
CLINICAL TRIALS ARENA
Ex-Metacrine chief Preston Klassen recharges at microRNA biotech
16 Jun 2023 //
ENDPTS
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral
15 Jun 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Announces Departure of Chief Financial Officer
14 Jun 2023 //
GLOBENEWSWIRE
Allogene Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma
03 Jun 2023 //
GLOBENEWSWIRE
Allogene Announces Participation in Three Upcoming Investor Conferences
24 May 2023 //
GLOBENEWSWIRE
Allogene Announces Encore Presentation of PI Data from the ALLO-501/501A Trials
11 May 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Reports 1Q 2023 Financial Results and Business Update
03 May 2023 //
GLOBENEWSWIRE
Allogene Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials
26 Apr 2023 //
GLOBENEWSWIRE
Allogene Therapeutics to Report 1Q 2023 FYR on May 3, 2023
25 Apr 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
20 Apr 2023 //
GLOBENEWSWIRE
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316
17 Apr 2023 //
GLOBENEWSWIRE
Allogene Announces Participation in Four Upcoming Investor Conferences
13 Apr 2023 //
GLOBENEWSWIRE
Allogene Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
30 Mar 2023 //
GLOBENEWSWIRE
